NCT02650752View on ClinicalTrials.gov

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 6, 2016

Primary Completion Date

January 22, 2021

Study Completion Date

January 22, 2021

Conditions
Metastatic Breast CancerCentral Nervous System (CNS) Metastases
Interventions
DRUG

Lapatinib in Tandem With Capecitabine

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11432

Queens Cancer Center of Queens Hospital, Jamaica

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

48109

University of Michigan Health System, Ann Arbor

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
collaborator

Queens Cancer Center of Queens Hospital

OTHER

collaborator

University of Michigan

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02650752 - Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases | Biotech Hunter | Biotech Hunter